Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Venture targets specialty drugs

May 22, 2006 | A version of this story appeared in Volume 84, Issue 21

Vectura Group and Unilever Ventures have spun off portions of their technology platforms to form the specialty pharmaceutical company PharmaKodex. The new firm will develop drugs by repurposing existing drugs for new indications or by improving the way they are administered. Vectura is contributing oral and dermal technologies; Unilever Ventures is contributing a particle formulation/solubilization nanotechnology from Iota NanoSolutions, another Unilever spin-off, and encapsulation technology from its parent, Unilever PLC.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.